{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1010000781977526657.json","@type":"Article","resourceType":"学術雑誌論文(journal article)","dc:title":[{"@language":"ja","@value":"Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one)."}],"publication":{"prism:publicationName":[{"@language":"ja","@value":"Drug Metab Dispos 35"}],"prism:publicationDate":"2007","prism:startingPage":"2045","prism:endingPage":"52"},"reviewed":"true","project":[{"@id":"https://cir.nii.ac.jp/crid/1040000781977526656","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"18059007"},{"@type":"JGN","@value":"JP18059007"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18059007/"}],"notation":[{"@language":"ja","@value":"トランスポートソームの機能制御による医薬品体内動態の制御"}]}],"dataSourceIdentifier":[{"@type":"KAKEN","@value":"PRODUCT-10844566"}]}